For the year ending 2025-12-31, ACAD had -$142,819K decrease in cash & cash equivalents over the period. $105,146K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 391,000 |
| Stock-based compensation | 52,135 |
| Amortization of premiums and accretion of discounts on investment securities | 5,424 |
| Amortization of intangible assets | 10,889 |
| Gain on sale of non-financial asset | 0 |
| Gain on strategic investment | 0 |
| Depreciation | 871 |
| Loss on sale of investment securities | 0 |
| Deferred income taxes (including benefit from valuation allowance) | -249,879 |
| Accounts receivable, net | 22,718 |
| Interest and other receivables | 20,818 |
| Inventory | 18,197 |
| Prepaid expenses and other current assets | 3,845 |
| Operating lease right-of-use assets | -8,667 |
| Other assets | 2,856 |
| Accounts payable | -5,289 |
| Accrued liabilities | -19,265 |
| Operating lease liabilities | -6,516 |
| Long-term liabilities | 1,081 |
| Net cash provided by operating activities | 109,836 |
| Purchases of investment securities | 692,565 |
| Sale and maturity of investment securities | 493,529 |
| Proceeds from sale of non-financial asset | 0 |
| Proceeds from sales of strategic investment | 0 |
| Net purchases of property and equipment | 4,690 |
| Payment of milestone and contingent payments in connection with asset acquisition | 98,838 |
| Net cash (used in) provided by investing activities | -302,564 |
| Proceeds from issuance of common stock, net of issuance costs | 49,883 |
| Net cash provided by financing activities | 49,883 |
| Effect of exchange rate changes on cash | 26 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -142,819 |
| Beginning of period | 328,359 |
| End of period | 185,540 |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)